The Cooper Companies, Inc. (NASDAQ: COO) is a Healthcare company in the Medical - Instruments & Supplies industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | S&P 500 | P/E | 62.91 | EPS (ttm) | 1.18 | Insider Own | 0.61% | Shs Outstand | 195.03M | Perf Week | 2.64% |
| Market Cap | 14.48B | Forward P/E | 14.82 | EPS next Y | 5.01 | Insider Trans | 0.00% | Shs Float | 193.67M | Perf Month | 4.52% |
| Enterprise Value | 16.80B | PEG | - | EPS next Q | 1.11 | Inst Own | - | Short Float | 4.09% | Perf Quarter | 21.47% |
| Income | 235.98M | P/S | 3.42 | EPS this Y | 292.49% | Inst Trans | - | Short Ratio | 2.72 | Perf Half Y | -7.33% |
| Sales | 4.23B | P/B | 1.76 | EPS next Y | 8.11% | ROA | 1.89% | Short Interest | 7.92M | Perf YTD | -9.43% |
| Book/sh | - | P/C | 15.19 | EPS next 5Y | 7.74% | ROE | 2.84% | 52W High | 91.65 -17.37% | Perf Year | 8.97% |
| Cash/sh | - | P/FCF | 25.42 | EPS past 3/5Y | -1.22% -17.22% | ROIC | 2.52% | 52W Low | 60.08 26.05% | Perf 3Y | -23.44% |
| Dividend Est. | 0.01 (0.01%) | EV/EBITDA | 19.40 | Sales past 3/5Y | 7.35% 10.98% | Gross Margin | 64.37% | Volatility | 2.17% 2.20% | Perf 5Y | -29.60% |
| Dividend TTM | - | EV/Sales | 3.97 | EPS Y/Y TTM | -39.80% | Oper. Margin | 11.77% | ATR (14) | 1.78 | Perf 10Y | 64.08% |
| Dividend Ex-Date | Jul 26, 2023 | Quick Ratio | 0.78 | Sales Y/Y TTM | 8.63% | Profit Margin | 5.57% | RSI (14) | 60.46 | Recom | 2.40 |
| Dividend Gr. 3/5Y | 0.00% 0.00% | Current Ratio | 1.27 | EPS Q/Q | 26.04% | SMA20 | 3.06% | Beta | 0.81 | Target Price | 76.80 |
| Payout | 0.00% | Debt/Eq | 0.30 | Sales Q/Q | 7.98% | SMA50 | 7.15% | Rel Volume | 0.56 | Prev Close | 74.23 |
| Employees | 15,000 | LT Debt/Eq | 0.33 | Earnings | Sep 09 | SMA200 | 1.48% | Avg Volume | 2.81M | Price | 75.73 |
| IPO Date | Jan 21, 1983 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 9.64% 2.63% | Net Debt/EBITDA | 2.68 | Volume | 1,561,687 | Change | 2.02% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jun-05-26 | Reiterated | Wells Fargo | Equal Weight | $66 |
| Jun-05-26 | Reiterated | Needham | Buy | $99 → $86 |
| Jun-04-26 | Reiterated | Mizuho | Outperform | $100 → $85 |
| Jun-01-26 | Reiterated | Piper Sandler | Overweight | $94 → $86 |
| May-27-26 | Reiterated | Goldman Sachs | Sell | $69 → $61 |
| Feb-03-26 | Reiterated | Needham | Buy | $100 → $99 |
| Jan-26-26 | Reiterated | Barclays | Overweight | $91 → $98 |
| Jan-09-26 | Reiterated | Goldman Sachs | Sell | $71 → $73 |
| Dec-08-25 | Reiterated | Barclays | $85 → $91 | |
| Dec-08-25 | Reiterated | Goldman Sachs | Sell | $64 → $71 |
The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses. Their product range includes spherical lenses for common vision issues like nearsightedness and farsightedness, as well as advanced lenses such as toric for astigmatism, multifocal for presbyopia, and specialized options addressing myopia, dry eyes, and eye fatigue. These vision correction solutions are available across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Meanwhile, CooperSurgical is dedicated to women's and family health, providing a wide array of medical devices, fertility treatments, genetic testing, diagnostic tools, and contraceptives to healthcare providers and patients globally. This segment's offerings encompass various surgical and office-based products like PARAGARD (an IUD), uterine manipulators, retractors, and closure devices. It also delivers comprehensive fertility services, including specialized consumables, equipment, embryo services, and preimplantation genetic screening. Established in 1958, The Cooper Companies, Inc. is headquartered in San Ramon, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 10/31/2025 | FY 2024 10/31/2024 | FY 2023 10/31/2023 | FY 2022 10/31/2022 | FY 2021 10/31/2021 | FY 2020 10/31/2020 | FY 2019 10/31/2019 | FY 2018 10/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 4,231 | 4,092 | 3,895 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 1,507 | 1,610 | 1,300 | — | — | — | — | — | — | |
| Gross Profit | 2,723 | 2,483 | 2,596 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 1,907 | 1,628 | 1,534 | — | — | — | — | — | — | |
| Research and Development | 173 | 172 | 155 | — | — | — | — | — | — | |
| Other Operating Expense | 145 | 0 | 201 | — | — | — | — | — | — | |
| Operating Income | 498 | 683 | 706 | — | — | — | — | — | — | |
| Interest Expense | 92 | 100 | 114 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 9 | -16 | -9 | — | — | — | — | — | — | |
| Net Income Before Taxes | 413 | 567 | 582 | — | — | — | — | — | — | |
| Income Taxes | 177 | 192 | 190 | — | — | — | — | — | — | |
| Consolidated Net Income | 236 | 375 | 392 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 236 | 375 | 392 | — | — | — | — | — | — | |
| Net Income | 236 | 375 | 392 | — | — | — | — | — | — | |
| EPS (Recurring) | 1.18 | 1.88 | 1.97 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 1.18 | 1.88 | 1.97 | — | — | — | — | — | — | |
| EPS (Diluted) | 1.18 | 1.87 | 1.96 | — | — | — | — | — | — | |
| EBITDA | 866 | 1,053 | 1,072 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 64.18 | 37.39 | 53.41 | — | — | — | — | — | — | |
| Price To Sales Ratio | 3.49 | 3.42 | 5.35 | — | — | — | — | — | — | |
| Gross Margin | 64.36 | 60.68 | 66.65 | — | — | — | — | — | — | |
| Operating Margin | 11.77 | 16.69 | 18.13 | — | — | — | — | — | — | |
| Net Margin | 5.58 | 9.16 | 10.06 | — | — | — | — | — | — | |
| Shares Outstanding | 195 | 200 | 199 | — | — | — | — | — | — | |
| Market Capitalization | 14,767 | 13,982 | 20,831 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Rosebrough Walter M Jr | Director | Apr 01 '26 | Option Exercise | 0.00 | 832 | 0 | 832 | Apr 21 |
| Carbone Barbara | Director | Apr 01 '26 | Option Exercise | 0.00 | 3,050 | 0 | 3,050 | Apr 06 |
| MADDEN TERESA S | Director | Apr 01 '26 | Option Exercise | 0.00 | 3,322 | 0 | 15,679 | Apr 06 |
| Lucchese Cynthia L | Director | Apr 01 '26 | Option Exercise | 0.00 | 3,322 | 0 | 12,767 | Apr 06 |
| Kurzius Lawrence Erik | Director | Apr 01 '26 | Option Exercise | 0.00 | 3,322 | 0 | 11,099 | Apr 06 |
| Rivas Maria | Director | Apr 01 '26 | Option Exercise | 0.00 | 3,322 | 0 | 3,322 | Apr 06 |
| Jay Colleen | Director | Apr 01 '26 | Option Exercise | 0.00 | 3,322 | 0 | 39,907 | Apr 06 |
| WEISS ROBERT S | Director | Apr 01 '26 | Option Exercise | 0.00 | 3,654 | 0 | 292,599 | Apr 06 |
| Jay Colleen | Director | Jan 12 '26 | Option Exercise | 39.40 | 7,064 | 278,322 | 36,585 | Jan 14 |
| McBride Daniel G | EVP & Chief Operating Officer | Jan 08 '26 | Option Exercise | 0.00 | 12,887 | 0 | 76,007 | Jan 12 |
| Andrews Brian G | EVP, CFO & Treasurer | Jan 08 '26 | Option Exercise | 0.00 | 3,528 | 0 | 10,430 | Jan 12 |
| Warner Gerard H III | President, CooperVision, Inc. | Jan 08 '26 | Option Exercise | 0.00 | 11,518 | 0 | 29,837 | Jan 12 |
| White Albert G III | President & CEO | Jan 08 '26 | Option Exercise | 0.00 | 18,340 | 0 | 254,491 | Jan 12 |
| Sheffield Holly R | President, CSI | Jan 08 '26 | Option Exercise | 0.00 | 8,050 | 0 | 47,102 | Jan 12 |
| Lucchese Cynthia L | Director | Dec 22 '25 | Buy | 84.06 | 1,784 | 149,963 | 9,445 | Dec 23 |